The Importance of Periostin in Periodontal Health and Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to determine the clinical importance of Periostin in oral health and disease. The long-term goal will be to develop practical applications for the diagnosis, treatment, prevention and cure of human periodontal diseases.
| Condition |
|---|
|
Periodontal Disease Healthy Patients |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | The Importance of Periostin in Periodontal Health and Disease |
- To determine whether the expression of Periostin within the periodontal tissues is affected in periodontal disease progression in-vivo and whether Periostin levels are associated with disease susceptibility. [ Time Frame: Baseline ] [ Designated as safety issue: No ]Periostin levels from gingival crevicular fluid (GCF), saliva, serum and tissue will be analyzed in both health and disease. Total RNA and protein extracts will be isolated and utilized for relative quantitative measurements.
- explore the expression dynamics of Periostin during periodontal healing in healthy and diseased periodontia. [ Time Frame: 8wks ] [ Designated as safety issue: No ]A longitudinal study will also be performed to evaluate Periostin levels in GCF/wound fluids and saliva over time during periodontal tissue healing and homeostasis.
Biospecimen Retention: Samples With DNA
Each patient will be have 5ml of blood collected at 3 different visits. Saliva, and gingival crevicular fluid will also be collected at 7-8 visits during the study. Gingival tissue will be collected on the day of surgery.
| Estimated Enrollment: | 22 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Periodontal disease
11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
|
|
Healthy periodontium
11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
|
Detailed Description:
It is hypothesized that Periostin levels are decreased during periodontal diseases, thereby, elevating the hosts' susceptibility to periodontal breakdown. The specific aims are the following; To determine if Periostin is a biomarker of periodontal disease, and To evaluate Periostin in periodontal tissue healing and homeostasis by harvesting healthy or diseased tissue from 22 patients requiring periodontal surgery.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
This study will have a sample size of 22 subjects: 11 periodontally healthy and 11 with periodontal disease.
Inclusion Criteria:
Inclusion criteria for diseased subjects:
- Diagnosis of generalized chronic or aggressive periodontitis
- At least four periodontal sites with probing depth (PD) ≥6 mm, evidence of clinical attachment loss (CAL), and bleeding on probing (BOP). Inclusion criteria for healthy individuals will include PD <4 mm, no evidence of attachment loss, and <10% of sites with BOP
- Need an open flap procedure
Inclusion criteria for non-diseased subjects:
- Subjects requiring a gingivectomy or crown lengthening procedure
Exclusion Criteria:
- History of alcoholism or drug abuse
- Medical conditions that may affect the outcome such as autoimmune diseases, diabetes, immunocompromised subjects, neurologic or psychiatric disorders, systemic infections, etc.
- Chronic medications known to affect the periodontal status (calcium antagonists, anticonvulsives, immunosuppressives, anti-inflammatory medications, Depo-Provera contraceptive injection users, new oral contraceptives users within 3 months of baseline or subjects that are planning on, starting oral contraceptives during the study.
- Antibiotic therapy within 3 months of the baseline visit, and/or antibiotic therapy needed for infective endocarditis prophylaxis.
- Current use or quit smoking less than one year ago with a pack-year history of more than or equal to 10.
- Untreated cavities
Contacts and Locations| Contact: Lea M Franco, MS, BS | (734) 998 - 6721 | mcohrclinicalresearch@umich.edu |
| Contact: Anna M Galloro, BS, MT | (734) 998 - 6721 | mcohrclinicalresearch@umich.edu |
| United States, Michigan | |
| Michigan Center for Oral Health Research | Recruiting |
| Ann Arbor, Michigan, United States, 48106 | |
| Principal Investigator: Hector Rios, MS, DDS | |
| Principal Investigator: | Hector Rios, MS, DDS | University of Michigan |
| Study Director: | William V Giannobile, DDS, DMSc | University of Michigan |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Principal Investigator: Hector Rios, MS, DDS, University of Michigan |
| ClinicalTrials.gov Identifier: | NCT01180920 History of Changes |
| Other Study ID Numbers: | HUM00038150 |
| Study First Received: | August 10, 2010 |
| Last Updated: | September 3, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Michigan:
|
Dental Periodontal Surgery Gums |
Additional relevant MeSH terms:
|
Periodontal Diseases Mouth Diseases Stomatognathic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013